Press release
North America Fabry Disease Treatment Market to Reach USD 2,173.14 Million by 2034 | Exhibiting a CAGR of 6.8%
The North America Fabry disease treatment market report offers an in-depth analysis of the rapidly evolving sector. It includes quantitative and qualitative analysis to provide insights into the current market state and expected growth trajectory. An assessment of the key regions, top segments, and competitive landscape has been provided.
The report reveals that the North America Fabry disease treatment market was valued at USD 1,122.24 million in 2024. With a CAGR of 6.8% during 2025-2034, the market is projected to grow to USD 2,173.14 million by 2034.
Get Exclusive Sample Pages of This Report: https://www.polarismarketresearch.com/industry-analysis/north-america-fabry-disease-treatment-market/request-for-sample
Market Introduction
Fabry disease treatment involves a combination of therapies aimed at managing symptoms, slowing disease progression, and improving the patient's quality of life. Fabry disease is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. The deficiency of the enzyme leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) in various tissues. The most widely recommended treatment for Fabry disease is enzyme replacement therapy (ERT). ERT involves regular intravenous infusions of synthetic alpha-galactosidase A to reduce GL-3 buildup and alleviate symptoms. In recent years, chaperone therapy has also emerged as an option for certain patients with specific genetic mutations.
Market Dynamics
High Diagnostic Rates: North America boasts an advanced healthcare system. This enables the widespread use of genetic screening, which plays a crucial role in identifying Fabry disease at an early stage. Early diagnosis prevents patient complications by enabling patients to begin treatment before the disease has progressed. The adoption of next-generation sequencing and enzyme testing as standard tools by hospitals in the region has made it easier to screen high-risk individuals, further contributing to the market development.
Technological Advancements in Patient Monitoring: Technological advancements in patient monitoring are revolutionizing the management of Fabry disease. The adoption of wearable medical devices and digital health platforms has enabled continuous symptom tracking and patient response. These tools provide healthcare professionals with real-time data on patient well-being.
Market Key Players
The market has the presence of several established players. These players are focusing on strategic initiatives to garner a major market share. A few of the major market participants include:
• Chiesi Farmaceutici S.p.A.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Sanofi
• Takeda Pharmaceutical
• Amicus Therapeutics, Inc.
• Idorsia Pharmaceuticals Ltd.
• Idorsia Pharmaceuticals Ltd.
• ISU ABXIS Co., Ltd.
• Sangamo Therapeutics, Inc.
Request for a Discount on this Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/north-america-fabry-disease-treatment-market/request-for-discount-pricing
Fabry Disease Treatment Industry Development
In March 2024, CENTOGENE expanded its partnership with Takeda to enhance access to genetic testing for individuals affected by lysosomal storage disorders (LSDs). The collaboration focuses on advancing genetic diagnostics to enable timely and accurate identification, supporting improved disease management and treatment outcomes.
Segmental Analysis :
By Route of Administration Outlook (Revenue USD Million, 2020-2034)
Intravenous Route
Oral Route
By Therapy Outlook (Revenue USD Million, 2020-2034)
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Others
By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Explore The Complete Comprehensive Report Here: https://www.polarismarketresearch.com/industry-analysis/north-america-fabry-disease-treatment-market
Country-Wise Insights
The US accounted for over 85% share of the North America Fabry disease treatment market. This is primarily due to its advanced healthcare infrastructure and early adoption of innovative therapies. In addition, the presence of a robust clinical ecosystem contributes to the country's leading market share.
Canada is anticipated to register a CAGR of 6.7% during the projection period. The market growth in Canada is fueled by improvements in diagnostic infrastructure and growing government support for rare disease programs. The rising adoption of newborn screening initiatives further contributes to faster treatment interventions.
More Trending Latest Reports by Polaris Market Research:
https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market
https://www.polarismarketresearch.com/industry-analysis/cryotherapy-market
https://www.polarismarketresearch.com/industry-analysis/ct-scanner-market
https://www.polarismarketresearch.com/industry-analysis/iv-tubing-sets-accessories-market
https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release North America Fabry Disease Treatment Market to Reach USD 2,173.14 Million by 2034 | Exhibiting a CAGR of 6.8% here
News-ID: 4090372 • Views: …
More Releases from Polaris Market Research and Consulting
In Situ Hybridization Market Size Set to Hit USD 3,015.57 Million by 2034, Growi …
Polaris Market Research has released new insights into the In Situ Hybridization market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 1,546.93 million and is anticipated to grow to USD 3,015.57 million by…
Next Generation Sequencing Sample Preparation Market Size Set to Hit USD 16.57 B …
Polaris Market Research has released new insights into the Next Generation Sequencing Sample Preparation market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 4.09 billion and is anticipated to grow to USD 16.57…
Plastic Welding Equipment Market Projected to Reach USD 2.69 Billion by 2034 , R …
Polaris Market Research announces the release of its latest study on the Plastic Welding Equipment market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at USD 1.60 billion in 2024 and is expected to reach USD…
DNA Manufacturing Market Projected to Reach USD 21.82 Billion by 2034, Registeri …
Polaris Market Research announces the release of its latest study on the DNA Manufacturing market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at USD 5.59 billion in 2024 and is expected to reach USD 21.82…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
